Zeno Albisser

Zeno Albisser is the CEO of Hemispherian, a Norwegian biotech company pioneering DNA-damage-response therapeutics for hard-to-treat cancers. He led Hemispherian into a joint venture with BioLineRx to advance its lead compound, GLIX1, into clinical development for glioblastoma. With a decade of leadership across pharmaceuticals, software, medical devices, defense, electronics, he combines computer science, finance, entrepreneurship to bridge technology and life sciences. Zeno holds an Executive MBA from BI Norwegian Business School Master’s in Computer Science.